UiPath's competitive edge lies in its AI integration, SAP partnership and industry-agnostic automation solutions, making it a strong contender in RPA despite generative AI threats. Recent struggles ...

Investors who choose to buy UiPath (NYSE: PATH) stock today must be comfortable with a hefty degree of uncertainty, considering there are important, unanswered questions around the business right now.

UiPath Inc. today announced a preview of its upcoming Agent Builder tool as it outlined its vision to combine its expertise in robotic process automation with generative artificial intelligence models ...

UiPath (PATH) has crashed so hard since the most recent earnings report that it is one of the few tech stocks that is still trading at around the 2022 lows. What happened? It appears that the market ...

Palantir (NYSE: PLTR) and UiPath (NYSE: PATH) represent two different ways to invest in the growing artificial intelligence (AI) market. Palantir mines data from disparate sources to help its ...

Automation has evolved. Where a decade ago we were happy (if not positively exhilarated) to talk about the application of intelligent document processing and robotic process automation as progressive ...

NEW YORK--(BUSINESS WIRE)--UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced it has opened nominations for the UiPath AI25 Awards. The annual awards program ...

UiPath Inc. (NYSE:PATH) is one of the best mid cap AI stocks to buy right now. UiPath Inc. (NYSE:PATH) is one of the best midcap AI stocks to buy right now. On August 1, 2025, UiPath announced the ...

UiPath launches AI-based Medical Record Summarization tool, reducing processing time from 45 minutes to minutes. Powered by Google Cloud, the agent improves accuracy, saves 40 minutes per referral, ...

C3.ai, Inc. AI and UiPath Inc. PATH are both high-profile players in the booming AI automation sector. C3.ai specializes in enterprise AI applications, including predictive maintenance and generative ...